sirolimus and Macroglossia

sirolimus has been researched along with Macroglossia* in 2 studies

Other Studies

2 other study(ies) available for sirolimus and Macroglossia

Article	Year
Efficacy of sirolimus in the treatment of microcystic lymphatic malformation of the tongue. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:9 Topics: Female; Humans; Immunosuppressive Agents; Infant; Lymphatic Abnormalities; Macroglossia; Sirolimus	2019
Successful Treatment of Macroglossia Due to Lymphatic Malformation With Sirolimus. The Annals of otology, rhinology, and laryngology, 2015, Volume: 124, Issue:10 To evaluate the effectiveness and safety of sirolimus therapy in a child with macroglossia due to lymphatic malformation.. Sirolimus treatment was applied to the patient with an initial dosing of 0.8 mg/m2 per dose, administered orally, twice daily at approximately 12-hour intervals.. After 9 months of sirolimus therapy, there was a nearly complete resolution of lymphatic malformation. The last evaluation was performed 6 months after withdrawal of treatment, and the lesion had almost completely resolved.. This article presents a novel approach to the treatment of lymphatic malformation of the tongue using sirolimus, which appears to be safe and effective for the management of complex cases. Topics: Administration, Oral; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Infant; Lymphatic Abnormalities; Macroglossia; Sirolimus; Treatment Outcome	2015

Article

Year

Efficacy of sirolimus in the treatment of microcystic lymphatic malformation of the tongue.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:9

Topics: Female; Humans; Immunosuppressive Agents; Infant; Lymphatic Abnormalities; Macroglossia; Sirolimus

2019

Successful Treatment of Macroglossia Due to Lymphatic Malformation With Sirolimus.

The Annals of otology, rhinology, and laryngology, 2015, Volume: 124, Issue:10

To evaluate the effectiveness and safety of sirolimus therapy in a child with macroglossia due to lymphatic malformation.. Sirolimus treatment was applied to the patient with an initial dosing of 0.8 mg/m2 per dose, administered orally, twice daily at approximately 12-hour intervals.. After 9 months of sirolimus therapy, there was a nearly complete resolution of lymphatic malformation. The last evaluation was performed 6 months after withdrawal of treatment, and the lesion had almost completely resolved.. This article presents a novel approach to the treatment of lymphatic malformation of the tongue using sirolimus, which appears to be safe and effective for the management of complex cases.

Topics: Administration, Oral; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Infant; Lymphatic Abnormalities; Macroglossia; Sirolimus; Treatment Outcome

2015